Motor Function Measure: validation of a short form (MFM-20) for young children with neuromuscular diseases
Capucine de Lattre, Christine Payan, Carole Vuillerot, Pascal Rippert, Denis de Castro, Carole Bérard, Isabelle Poirot and the MFM-20 Study Group.
Arch Phys Med Rehabil. 2013. 94 : 2218-26.
Validation of MFM version useful in neuromuscular children under 7 years old, the MFM-20. MFM-32 was completed on 194 healthy children aged 2-7 years. Twenty items of the MFM-32 were successfully completed by these children and were used to constitute the MFM-20. 88 children with a neuromuscular disease were rated by the MFM by a trained medical professional. Principal component analysis of the MFM-20 confirmed the 3 functional domains of the MFM (D1, D2 and D3). Inter- and intra-rater reliability of the 3 sub-scores and total score were high (ICC > 0.90) and discriminant validity was good. The MFM-20 can be used as an outcome measure for assessment of motor function in young children with a neuromuscular disease.
Keywords: Neuromuscular disease, Motor function, Disability evaluation, Rehabilitation, Metrology
Articles dans les revues scientifiques
High-frequency, low-intensity vibrations increase bone mass and muscle strength in upper limbs, improving autonomy in disabled children
Reyes ML, Hernandez M, Holmgren LJ, Sanhueza E, Escobar RG. J Bone Miner Res, 2011. 26(8): 1759-66. The main objective of this study was to evaluate the efficacy and safety of high-frequency, low-magnitude vibration, in patients with disabilities. 55 children were a...
Motor Function Measure Scale (MFM): New Instrument for Follow-Up Brazilian Patients with Neuromuscular Disease
Iwabe C, Nucci A, Pfeilsticker BHM, Magna LA. Muscular Dystrophy ed.Croacia : Intech. 2012. 303-320. Book chapter presenting the validation and applicability of the MFM Portuguese version.Link Articles dans les revues scientifiques
Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease
Orlikowski D, Pellegrini N, Prigent H, Laforêt P, Carlier R, Carlier P, Eymard B, Lofaso F, Annane D. Neuromuscul Disord. 2011. 21(7):477-82. This open-label prospective exploratory study investigated the effect of 12 months of recombinant enzyme replacement therapy...
Upper limb function in adults with Duchenne muscular dystrophy
Bartels G, Pangalila RF, Bergen MP, Cobben NAM, Stam HJ, Roebroeck ME. J Rehabil Med 2011. 43(9) : 770-5. This study illustrates a large variability in upper limb function in adult patients with Duchenne muscular dystrophy, and identifies muscle strength and range of...
Fonction musculaire et atteinte d’organes dans la dystrophie myotonique de type 1
Pruna L, Machado F, Louis L, Vassé G, Kaminsky P. Revue Neurologie 2011. 167: 23-28. The aim of this study, carried out on 69 patients with type 1 myotonic dystrophy, was to assess the correlations between the MFM score and some organ impairments. The MFM provides an...
Regional body composition and functional impairment in patients with Myotonic Dystrophy
Pruna L, Chatelin J, Pascal-Vigneron V, Kaminsky P. Muscle nerve 2011. 44(4) : 503-8. In this study, fat-free mass index (FFMI), fat mass index (FMI) and functional impairment were examined in 48 patients with myotonic dystrophy type 1 subjects and anthropometrically...